Unicycive Therapeutics (UNCY) Assets Average (2021 - 2026)
Unicycive Therapeutics' (UNCY) quarterly Assets Average came in at $56.8 million in Q1 2026, up 90.46% YoY from $29.8 million in Q1 2025, and up 13.83% on a QoQ basis from $49.9 million in Q4 2025.
Unicycive Therapeutics (UNCY) Assets Average (2021 - 2026) Analysis & Trends
Unicycive Therapeutics (UNCY) has 6 years of Assets Average data on file, last reported at $56.8 million in Q1 2026.
- Quarterly Assets Average rose 90.46% year-over-year to $56.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $56.8 million (up 90.46% YoY) and the FY2025 annual result came in at $40.4 million, up 76.2% from the prior year.
- Assets Average climbed to $56.8 million in Q1 2026, from $49.9 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $56.8 million in Q1 2026 to a low of $6.5 million in Q4 2022.
- A 5-year average of $28.9 million and a median of $29.0 million in 2025 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2022 — Assets Average slumped 66.27% — and 2023, when it jumped 158.81%.
- Tracing UNCY's Assets Average over 5 years: stood at $6.5 million in 2022, then jumped by 158.81% to $16.8 million in 2023, then surged by 108.85% to $35.1 million in 2024, then surged by 42.0% to $49.9 million in 2025, then climbed by 13.83% to $56.8 million in 2026.
- The last three Assets Average figures came in at $56.8 million (Q1 2026), $49.9 million (Q4 2025), and $40.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Unicycive Therapeutics | 147.24 Mn | 147.24 Mn | - | 68.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 68.22 Mn |
| Mar 31, 2026 | 56.77 Mn |
| Dec 31, 2025 | 49.87 Mn |
| Sep 30, 2025 | 40.30 Mn |
| Jun 30, 2025 | 28.97 Mn |
| Mar 31, 2025 | 29.81 Mn |
| Dec 31, 2024 | 35.12 Mn |
| Sep 30, 2024 | 41.64 Mn |
| Jun 30, 2024 | 48.54 Mn |
| Mar 31, 2024 | 33.29 Mn |
| Dec 31, 2023 | 16.82 Mn |
| Sep 30, 2023 | 21.16 Mn |
| Jun 30, 2023 | 25.04 Mn |
| Mar 31, 2023 | 15.01 Mn |
| Dec 31, 2022 | 6.50 Mn |
| Sep 30, 2022 | 11.50 Mn |
| Jun 30, 2022 | 14.29 Mn |
| Mar 31, 2022 | 17.25 Mn |
| Dec 31, 2021 | 19.26 Mn |
| Sep 30, 2021 | 10.35 Mn |